GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Float Percentage Of Total Shares Outstanding

BriaCell Therapeutics (TSX:BCT) Float Percentage Of Total Shares Outstanding : 87.67% (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BriaCell Therapeutics's float shares is 14.01 Mil. BriaCell Therapeutics's total shares outstanding is 15.98 Mil. BriaCell Therapeutics's float percentage of total shares outstanding is 87.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BriaCell Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BriaCell Therapeutics's Institutional Ownership is 1.73%.

BriaCell Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BriaCell Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=14.01/15.98
=87.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics (TSX:BCT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TSX:ONC TSX:TH XCNQ:DTC TSX:EPRX TSXV:ARCH TSXV:NGEN TSXV:MIR XCNQ:ACOG NEOE:MMED TSX:MBX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
BCTX:USA
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
Website
https://www.briacell.com
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines